Forbion

On April 8 Forbion Head of Impact and ESG Silva Deželan, PhD will be a panelist on Invest Europe's webinar "Sustainability in a changing geopolitical landscape: What you need to know." Silva will be joined by Erwann Le Ligné from Eurazeo, Heike Schmitz from Herbert Smith Freehills, Nils Rode from Schroders Capital, Anna Follér from the Sixth Swedish National Pension Fund / Sjätte AP-fonden and Eimear Palmer from Pantheon. The panel will explore: Navigating increasing policy uncertainty in PE, assessing the economic & strategic business impacts of the current landscape and managing the legal and contractual considerations in an evolving environment. Click on the following link to learn more: https://lnkd.in/e_WdySS9 #sustainability, #lifesciences #impact #patients #venturecapital #biotech #invest #europe

Forbion is expanding, and we are looking for exceptional talent to join our Ventures Fund team. We are seeking a Principal to help identify, invest in, and build breakthrough life sciences companies. This is an exciting opportunity to play a key role in shaping the next generation of biotech innovations. Locations: Naarden, Netherlands & Boston, USA To learn more & apply check out the following links: https://lnkd.in/gbZK5yyE and https://lnkd.in/g4pZVBFr We remain dedicated to driving life sciences innovation, and we need sharp, visionary minds to help us make a lasting impact. If you or someone in your network is ready for this challenge, we would love to connect! #careers #development #jobs #lifesciences #biotech #ventures #venturecapital Rory Gummerson

Forbion congratulates our portfolio company, RyCarma Therapeutics, on the appointment of Dr. Elizabeth Tarka as Chief Medical Officer. Dr. Tarka brings extensive expertise in cardiovascular drug development and will play a critical role in advancing surlorian (ARM210) into Phase 2 clinical trials for heart failure with reduced ejection fraction (HFrEF) and ryanodine receptor 1-related myopathies (RYR1-RM). We look forward to RyCarma’s continued progress in developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases. Read more using the following link: https://lnkd.in/eSRF7WJU #Forbion #RyCarmaTherapeutics #Biotech #Cardiovascular #lifesciences #biotech #MuscleDisease #Leadership Dr. Dmitrij Hristodorov Geert-Jan Mulder

Forbion is proud to announce that we have co-led a $155 million Series B financing in AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with both rare and common conditions. The round was led by Venrock Healthcare Capital Partners, co-led by Forbion Growth, and included participation from Forbion Ventures, RTW Investments, Nextech Invest, ARCH Venture Partners, ND Capital, and other new and existing investors. With this financing, AIRNA will advance its lead RNA editing candidate, AIR-001, into a Phase 1/2 clinical trial for Alpha-1 Antitrypsin Deficiency (AATD) and further develop a pipeline of novel RNA-editing medicines targeting cardiometabolic and other diseases. Click on the following link to learn more: https://lnkd.in/ecdFtkHF #lifesciences #biotech #investment Vanessa Carle Dirk Kersten Tim Lohoff, Ph.D. Melanie de Almeida

Some Monday morning career motivation! Are you an MD or PhD graduate eager to explore life sciences venture capital? Forbion’s Fellowship 2025 offers a unique opportunity to apply your scientific expertise to evaluate biotech innovations, analyze companies, and identify investment opportunities. Join our dynamic team in Naarden, The Netherlands for 6-9 months of hands-on experience in deal flow management, due diligence, and investment strategy. Gain exposure to leading biotech companies while developing your analytical and commercial skills. If you are ambitious, curious, and ready for a challenge, apply by May 2nd, 2025. Learn more and submit your application here: https://lnkd.in/ejsq59VN #careerdevelopment #careeropportunity #fellowship #moversandshakers #opportunity #lifesciences #biotech #doctorate #postdoc #investment #career

Forbion portfolio company Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors. He brings significant senior industry leadership, joining Purespring with over 25 years in the life sciences industry and an impressive track record of leading organisations to create blockbuster brands from primary care to rare diseases, across both mature and growth markets. Click on the following link to learn more: https://lnkd.in/e9VWsrce #lifesciences #portfoliocompany #news #appointment #venturecapital

Tomorrow, March 8, marks International Women's Day, a global celebration of the social, economic, cultural, and political achievements of women. At Forbion, we are proud to recognize and celebrate the incredible women who contribute to our success, drive innovation, and inspire positive change across the life sciences industry. We remain committed to fostering an inclusive environment where all talent can thrive. Together, we celebrate the women who lead, innovate, and uplift those around them. Click on the video below to hear directly from some of the women at Forbion as they share their advice and insights. Machteld Groeneveld, LLM, MBA Silva Deželan, PhD Jennifer Fritzsche Rachelle Young Nanna Lüneborg #InternationalWomensDay #IWD2025 #InspireInclusion #Forbion #lifesciences #biotech #leaders

Forbion portfolio company Orbis Medicines has named veteran R&D Leader Mikael Dolsten as its board chair. Dr. Dolsten was most recently CSO of Pfizer and has served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals. His appointment follows the transition of Morten Graugaard from Chairperson to CEO earlier this year. Click on the following link to learn more: https://lnkd.in/edYPBTnc #appointment #lifesciences #biotech

Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. She holds a PhD in protein engineering from Dartmouth College and a degree in biomedical engineering from Cornell University. Regina is already a familiar face to Forbion, having collaborated with us on several successful investments. As part of the Forbion Growth team, she will focus on private and crossover opportunities, bringing her deep expertise and strong network to further strengthen our efforts. We are excited to continue expanding our team with exceptional talent and to further grow our presence in the US. Welcome, Regina! Read more using the following link: https://lnkd.in/earVQrsK #Forbion #LifeSciences #VentureCapital #GrowthInvesting #Biotech Regina Salvat

Today, on 28 February, we recognize Rare Disease Day and the millions of people around the world living with rare diseases. At Forbion, we are proud to have supported the development of innovative gene therapies and other transformative treatments for rare diseases. Our work spans early innovation, scientific insight, entrepreneurial support, and long-term partnership - all essential elements in bringing these therapies to life. Learn more about our role and our investment approach in advancing gene therapies and supporting innovation in the rare disease space: https://lnkd.in/en-zHitb #RareDiseaseDay #RareDiseases #GeneTherapy #Forbion #Biotech #Innovation